share_log

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Sight Sciences將在即將舉行的美國銀行醫療保健會議上發表演講
GlobeNewswire ·  05/07 16:05

MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.

加州門洛帕克,2024年5月7日 /美通社/ -- 眼科技術公司Sight Sciences(納斯達克股票代碼: SGHT)(“Sight Sciences”或“公司”),專注於開發和商業化創新的干預性技術,提高醫療服務標準,今天宣佈將在即將召開的美國銀行醫療保健大會上發表演講,地點在內華達州拉斯維加斯。

Sight Sciences' management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: investors.sightsciences.com.

Sight Sciences的管理層將於2024年5月14日星期二上午8:15 PT / 11:15 ET進行演講。 有興趣的人可以在公司網站的“投資者”部分訪問演講的現場和存檔網絡廣播:investors.sightsciences.com。

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional technologies intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company's SION Surgical Instrument is a manually operated device available in the United States to be used in ophthalmic surgical procedures to excise trabecular meshwork.

關於Sight Sciences Sight Sciences是一家專注於開發和商業化創新和干預性技術,旨在改善患者生活狀況的眼科技術公司。Sight Sciences通過使用微創或非侵入性方法來針對全球最爲普遍的眼部疾病的根本原因,希望創造更有效的治療範例,以提高患者的護理,並替代過時的常規方法。該公司的OMNI手術系統是一種無植入物的青光眼手術技術(i)適用於美國成年患者的原發性開角型青光眼降低眼內壓;以及(ii)歐盟CE認證的用於導管和顯微增強Schlemm's canal和切割眼前房網狀組織以降低成年患者的眼內壓。青光眼是全球無法逆轉的失明的最主要原因。該公司的TearCare系統技術已在美國獲得510(k)清除用於成人因莫氏腺機能障礙( MGD)而出現的蒸發性乾眼症的局部加熱療法的申請,當與莫氏腺手動表達一起使用時,使醫生能夠清除腺體梗阻以解決乾燥眼病的主要原因。該公司的SION手術器械是一種手動操作的設備,可在美國用於眼科手術程序,以切除眼前房網狀組織。
Sight Sciences和TearCare是Sight Sciences在美國註冊的商標。OMNI,OMNI ERGO和SION是Sight Sciences在美國,歐盟和其他領地註冊的商標。

For more information, visit

要獲取更多信息,請訪問

Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, OMNI ERGO, and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

2024 Sight Sciences。保留所有權利。

2024 Sight Sciences. All rights reserved.

Media contact:
pr@SightSciences.com

媒體聯繫人:
pr@SightSciences.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

投資者聯繫人:
Philip Taylor
吉爾馬汀集團
415.937.5406
Investor.Relations@Sightsciences.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論